Prosecution Insights
Prosecution Insights
73 pending office actions • 29 art units • 69 examiners • 0 of 73 (0%) have an AI response strategy ready • 69 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 35 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 35 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (3%) |
| §103 only | 18 (25%) |
| §102 only | 4 (5%) |
| §112 only | 7 (10%) |
| Double-patenting only | 5 (7%) |
| Double-patenting + other | 12 (16%) |
| Multi-statute (no §101) | 25 (34%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 2 | 62.1% | +34.1% |
| SAMALA, JAGADISHWAR RAO | 2 | 67.9% | +55.5% |
| NATARAJAN, MEERA | 2 | 62.3% | +17.6% |
| DONOHUE, SEAN R | 2 | 41.4% | +21.1% |
| PERREIRA, MELISSA JEAN | 1 | 52.0% | +25.9% |
| MEJIAS, SAMANTHA LEE | 1 | 50.0% | +60.0% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +29.8% |
| BARSKY, JARED | 1 | 50.3% | +23.1% |
| ROSENTHAL, ANDREW S | 1 | 51.4% | +40.2% |
| REILLY, SOPHIA JANE | 1 | 60.6% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17766149 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | SCHMIDT, IZABELA MARIA | 264d overdue |
| 18015856 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | CHICKS, ASHLI ARIANA | 133d overdue |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | EBBINGHAUS, BRIANA NOEL | 30d overdue |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NICKOL, GARY B | 15d overdue |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | RAO, SAVITHA M | 8d overdue |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | SKOKO III, JOHN JOSEPH | 14d |
| 17629286 | REGULATABLE EXPRESSION SYSTEMS | LEVIN, JOEL D | 15d |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | NATARAJAN, MEERA | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 91d overdue |
| 18977210 | Ribociclib Tablet | FUBARA, BLESSING M | 88d overdue |
| 17997299 | METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 71d overdue |
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 70d overdue |
| 19240908 | METHOD OF TREATING PROSTATE CANCER | PERREIRA, MELISSA JEAN | 32d overdue |
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | NATARAJAN, MEERA | 2d overdue |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | NATARAJAN, MEERA | 21d |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | YOUNG, MICAH PAUL | 41d |
| Art Unit | Apps |
|---|---|
| 1618 | 8 |
| 1643 | 8 |
| 1674 | 4 |
| 1623 | 3 |
| 1647 | 3 |
| 1627 | 3 |
| 1632 | 3 |
| 1628 | 3 |
| 1675 | 3 |
| 1613 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19240908 | METHOD OF TREATING PROSTATE CANCER | PERREIRA, MELISSA JEAN | 1618 | §103 | Non-Final OA | 32d overdue | Pending | Jun 17, 2025 |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | MEJIAS, SAMANTHA LEE | 1618 | §103Other | Final Rejection | 76d | Pending | Jun 11, 2025 |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | YOUNG, MICAH PAUL | 1618 | §102§103 | Non-Final OA | 41d | Pending | Apr 11, 2025 |
| 18977210 | Ribociclib Tablet | FUBARA, BLESSING M | 1613 | §103DP | Final Rejection | 88d overdue | Pending | Dec 11, 2024 |
| 18851253 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | BARSKY, JARED | — | §112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18802089 | IMMUNOSUPPRESSANT FORMULATIONS | ROSENTHAL, ANDREW S | — | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18800559 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | REILLY, SOPHIA JANE | — | §102§112 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18836800 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | HABTE, KAHSAY | — | §112Other | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18739657 | COMBINATION | HUI, SAN MING R | — | §103 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18670859 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | PATEL, SAGAR S | — | §112Other | Non-Final OA | — | Pending | May 22, 2024 |
| 18628570 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | §102§112 | Final Rejection | — | Pending | Apr 05, 2024 |
| 18628097 | METHODS OF TREATING NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | CARTER, SANDRA DILLAHUNT | — | DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18588259 | Ribociclib Tablet | FUBARA, BLESSING M | 1613 | §102§103DP | Final Rejection | — | Pending | Feb 27, 2024 |
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | DP | Non-Final OA | 91d overdue | Pending | Feb 13, 2024 |
| 18423776 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18424004 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH | HAMA, JOANNE | — | DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18291083 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | LEE, WILLIAM Y | 1623 | §103 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18391485 | METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB | SZPERKA, MICHAEL EDWARD | — | §102§103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18569346 | PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY | LIU, SUE XU | 1646 | §102§103§112 | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18562108 | METHODS FOR THE TREATMENT OF OSTEOARTHRITIS | METCALF, MATTHEW CURRAN | 1647 | §101§102§103DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | RAO, SAVITHA M | 1691 | §102§103§112Other | Non-Final OA | 8d overdue | Pending | Nov 16, 2023 |
| 18510836 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | LEWIS, PATRICK T | 1691 | §103§112Other | Non-Final OA | 22d | Pending | Nov 16, 2023 |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | HERNANDEZ, JACKSON J | 1627 | §103DP | Final Rejection | 17d overdue | Pending | Nov 03, 2023 |
| 18558729 | TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS USING ANTI-BAFFR ANTIBODIES | MCCOLLUM, ANDREA K | 1674 | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18558415 | ALPELISIB FORMULATION | JUSTICE, GINA CHIEUN YU | 1617 | §103§112 | Non-Final OA | 28d | Pending | Nov 01, 2023 |
| 18497296 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | JAVANMARD, SAHAR | 1622 | DPOther | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18557772 | HYPERSIALYLATING CELLS | BERKE-SCHLESSEL, DAVID W | 1651 | §103§112 | Non-Final OA | 28d | Pending | Oct 27, 2023 |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18286030 | OFATUMUMAB FOR TREATING MULTIPLE SCLEROSIS IN ASIAN PATIENTS | CHHAY, BONIRATH | 1645 | §102§103§112Other | Non-Final OA | 34d | Pending | Oct 06, 2023 |
| 18552760 | DIAGNOSTIC METHODS OF PROSTATE CANCER | ROGERS, JAMES WILLIAM | 1618 | §103 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18551699 | NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | RAO, PADMAJA S | 1627 | §112 | Non-Final OA | 70d overdue | Pending | Sep 21, 2023 |
| 18551033 | NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | 34d | Pending | Sep 18, 2023 |
| 18281732 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | HEASLEY, MEGHAN CHRISTINE | 1626 | §103§112Other | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18550004 | HIGH THROUGHOUT SCREENING IN DROPLETS | BUNKER, AMY M | 1684 | §103 | Final Rejection | — | Pending | Sep 11, 2023 |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | SKOKO III, JOHN JOSEPH | 1643 | §102§103§112Other | Non-Final OA | 14d | Pending | Aug 08, 2023 |
| 18363207 | NLRP3 INFLAMMASOME INHIBITORS | HEES, OLIVER DRAGON | 1628 | §112 | Non-Final OA | 9d | Pending | Aug 01, 2023 |
| 18352345 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NIEBAUER, RONALD T | 1658 | DP | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18253903 | EXPRESSION TECHNOLOGY FOR ANTIBODY CONSTRUCTS | MONTANARI, DAVID A | 1632 | §103§112 | Non-Final OA | 55d | Pending | May 22, 2023 |
| 18035470 | CD19 BINDING MOLECULES AND USES THEREOF | KAUFMAN, CLAIRE M | 1674 | §103§112DP | Non-Final OA | — | Pending | May 04, 2023 |
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | NATARAJAN, MEERA | 1643 | §103Other | Non-Final OA | 2d overdue | Pending | May 04, 2023 |
| 18034326 | USE OF AN IL-18 ANTAGONIST FOR TREATING AND/OR PREVENTION OF ATOPIC DERMATITIS OR A RELATED CONDITION | BUNNER, BRIDGET E | 1647 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 18187242 | USE OF CANAKINUMAB | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | 34d | Pending | Mar 21, 2023 |
| 18184860 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | SKELDING, ZACHARY S | 1644 | §102 | Non-Final OA | — | Pending | Mar 16, 2023 |
| 18002572 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | CORNET, JEAN P | 1628 | §103 | Non-Final OA | 4d overdue | Pending | Dec 20, 2022 |
| 18009568 | ZBTB32 INHIBITORS AND USES THEREOF | RAHMAN, MASUDUR | 1633 | §102§103 | Final Rejection | — | Pending | Dec 09, 2022 |
| 18061824 | COMBINATION THERAPIES | CANELLA, KAREN A | 1643 | §102§103§112 | Non-Final OA | 33d | Pending | Dec 05, 2022 |
| 18061221 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | WU, JULIE ZHEN QIN | 1643 | §101§112Other | Non-Final OA | 49d | Pending | Dec 02, 2022 |
| 18061227 | METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | EDGINGTONGIORDANO, FRANCESCA | 1643 | DPOther | Non-Final OA | — | Pending | Dec 02, 2022 |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | NATARAJAN, MEERA | 1643 | §102§112 | Non-Final OA | 21d | Pending | Oct 28, 2022 |
| 17997299 | METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | 71d overdue | Pending | Oct 27, 2022 |
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | 70d overdue | Pending | Oct 27, 2022 |
| 17973773 | VERTEBRATE CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A POLYPEPTIDE OF INTEREST | NGUYEN, QUANG | 1631 | §112DP | Final Rejection | — | Pending | Oct 26, 2022 |
| 17938846 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | FORD, VANESSA L | 1674 | §103Other | Non-Final OA | 32d overdue | Pending | Oct 07, 2022 |
| 17760298 | THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR FOR USE IN TREATING BRAF MUTANT NSCLC | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Final Rejection | 58d overdue | Pending | Aug 05, 2022 |
| 17813843 | COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION | MARVICH, MARIA | 1634 | §112DP | Non-Final OA | — | Pending | Jul 20, 2022 |
| 17771353 | CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS | BERHANE, SELAM | 1675 | §103§112DP | Final Rejection | — | Pending | Apr 22, 2022 |
| 17761902 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | LEE, CHIHYI NMN | 1628 | §112DP | Non-Final OA | — | Pending | Mar 18, 2022 |
| 17642285 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BELL, SARA ELIZABETH | 1625 | §102§112 | Non-Final OA | — | Pending | Mar 11, 2022 |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | WANG, CHANG YU | 1675 | §103 | Final Rejection | 60d overdue | Pending | Mar 09, 2022 |
| 17753632 | TREATMENT OF RMS BY SWITCHING THERAPY | AEDER, SEAN E | 1600 | §103DP | Non-Final OA | — | Pending | Mar 09, 2022 |
| 17640293 | THERAPEUTIC FUSION PROTEINS | DEBERRY, REGINA M | 1647 | §112 | Non-Final OA | 19d overdue | Pending | Mar 03, 2022 |
| 17629286 | REGULATABLE EXPRESSION SYSTEMS | LEVIN, JOEL D | 1633 | §102§103 | Final Rejection | 15d | Pending | Jan 21, 2022 |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NICKOL, GARY B | 1643 | §102§112Other | Non-Final OA | 15d overdue | Pending | Dec 20, 2021 |
| 17613889 | METHOD FOR NAVIGATING MEDICAL DATA | LAM, ELIZA ANNE | 3681 | §103 | Non-Final OA | 2d overdue | Pending | Nov 23, 2021 |
| 17612280 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | — | Pending | Nov 18, 2021 |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112 | Non-Final OA | 30d overdue | Pending | Aug 25, 2021 |
| 17432868 | COMBINATION THERAPIES OF EGFRVIII CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | CHASE, CAROL ANN | 1646 | §102§103§112 | Final Rejection | — | Pending | Aug 20, 2021 |
| 17057561 | Automatic Drug Delivery Device | FREHE, WILLIAM R | 3783 | §103 | Non-Final OA | — | Pending | Nov 20, 2020 |
| 16980679 | METHODS FOR TREATING OCULAR DISEASES | FONTAINHAS, AURORA M | 1675 | §103Other | Non-Final OA | — | Pending | Sep 14, 2020 |
| 18566259 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | CHONG, YONG SOO | 1623 | §102Other | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18015856 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | CHICKS, ASHLI ARIANA | 1626 | §102§103§112 | Non-Final OA | 133d overdue | Pending | Jan 12, 2023 |
| 17766149 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | SCHMIDT, IZABELA MARIA | 1621 | §102§112Other | Non-Final OA | 264d overdue | Pending | Apr 01, 2022 |
| 17376829 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | SHTERENGARTS, SAMANTHA L | 1623 | §102 | Non-Final OA | 117d overdue | Pending | Jul 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial